Cell therapy for advanced stomach cancer with Claudin18.2 protein
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach, esophagus, or gastroesophageal junction cancer that tests positive for a protein called Claudin18.2.
- Your cancer has not been controlled by standard treatments or has continued to grow.
- You are between the ages of 18 and 75.
- You have not received any cell therapy (like CAR-T) in the past year, or any treatment that targets Claudin18.2.
- Your major organs (blood, liver, kidneys, heart) must be working well enough, as shown by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune therapy called CAR-T cells that target a protein called Claudin18.2 found on some solid tumors. The goal is to see if it can help shrink tumors in people who have already tried other treatments.
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
This trial tests a new type of cell therapy (CT041) given after surgery and chemotherapy to prevent stomach cancer from coming back. It is for people whose tumors have a specific protein (CLDN18.2) and who have already had standard treatment.
This study tests a new treatment using your own immune cells (called CAR-T and CAR-DC) that are engineered to attack cancer cells with a specific protein (Claudin18.2). It is for people with advanced colorectal cancer who have exhausted standard treatments.
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
Hear when a new Claudin18.2 Positive Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.